<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982982</url>
  </required_header>
  <id_info>
    <org_study_id>0901004662</org_study_id>
    <nct_id>NCT00982982</nct_id>
  </id_info>
  <brief_title>Effects of Delta-9-THC and Iomazenil in Healthy Humans</brief_title>
  <official_title>Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or
      THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity
      of the brain (EEG). THC is the active ingredient of marijuana, cannabis, &quot;ganja&quot;, or &quot;pot&quot;.
      Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to
      determine whether the administration of iomazenil will alter the effects of THC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered Dissociative Symptoms Scale</measure>
    <time_frame>On each test day at: baseline, +10min after infusion, +70min, +150min, +240min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and Negative Symptom Scale</measure>
    <time_frame>On each test day at: baseline, +10min after infusion, +70min, +150min, +240min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>On each test day at: baseline, +10min after infusion, +70min, +150min, +240min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Auditory Verbal Learning Test</measure>
    <time_frame>On each test day at: baseline, +10min after infusion, +70min, +150min, +240min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceptual Aberration Scale</measure>
    <time_frame>On each test day at: baseline, +10min after infusion, +70min, +150min, +240min</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Mental Disorders</condition>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>THC and Iomazenil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iomazenil: 3.7 μg/kg intravenously over 10 minutes
Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or &quot;joint&quot;. It is administered intravenously for 10 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control: small amount of alcohol intravenous (quarter teaspoon), with no THC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THC and Iomazenil</intervention_name>
    <description>Iomazenil: 3.7 μg/kg intravenously over 10 minutes
Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or &quot;joint&quot;. It is administered intravenously for 10 minutes.</description>
    <arm_group_label>THC and Iomazenil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (control)</intervention_name>
    <description>Control: small amount of alcohol intravenous (quarter teaspoon), with no THC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Exposed to cannabis at least once in their lifetime

        Exclusion Criteria:

          -  Cannabis naïve

          -  History of hearing deficit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak C D'Souza, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Deepak C. D'Souza</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Psychotic Disorders</keyword>
  <keyword>Schizophrenia and Disorders with Psychotic Features</keyword>
  <keyword>Cannabis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

